Capsule Summary Slidesets

Share

Program Content

Activities

  • Mitapivat for SCD
    Phase I Dose-Escalation Study of Mitapivat (AG-348) in Patients With Sickle Cell Disease
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2021

    Expires: December 16, 2022

  • SOLACE-kids
    SOLACE-kids: Phase II Study of Crizanlizumab in Adolescents With Sickle Cell Disease
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2021

    Expires: December 14, 2022

  • Iptacopan for PNH
    Phase II Study of Iptacopan Monotherapy for Paroxysmal Nocturnal Hemoglobinuria: A 12-Mo Analysis
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2021

    Expires: December 15, 2022

  • AREG: Monitoring in aGVHD
    Amphiregulin as a Monitoring Biomarker for Patients With Acute GVHD
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2021

    Expires: December 14, 2022

  • uhCG/EGF for aGVHD
    Phase II Trial of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor for Life-threatening Acute GVHD
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2021

    Expires: December 15, 2022

  • Axatilimab in cGVHD
    Phase I/II Study of Anti‒CSF-1R Antibody Axatilimab in Heavily Pretreated Chronic Graft-vs-Host Disease
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 22, 2021

    Expires: December 21, 2022

  • Abatacept for GVHD
    Abatacept for Steroid-Refractory Chronic GVHD: Results From a Phase II Clinical Trial
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2021

    Expires: December 16, 2022

  • ATLAS-INH: Fitusiran for Hemophilia A/B
    ATLAS-INH: Phase III Trial of Fitusiran Prophylaxis in Patients With Hemophilia A or B With Inhibitors
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 21, 2021

    Expires: December 20, 2022

  • Etavopivat in SCD
    Exploratory Analyses From a Phase I Study of Etavopivat in Sickle Cell Disease
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2021

    Expires: December 16, 2022

  • ATLAS-A/B
    ATLAS-A/B: Phase III Trial of Fitusiran, an Investigational siRNA Therapy Targeting Antithrombin, in Patients With Hemophilia A or B Without Inhibitors
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2021

    Expires: December 15, 2022

Provided by

ProCE Banner

Supporters

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation